Invest in

Drug-Patent Cliffs

25.1%
5.3%
0.0%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
25.1%
5.3%
0.0%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
100% Generic Drugs 22.8%
20.3% Dr. Reddy's Laboratories Ltd RDY 11.9%
20.3% Taro Pharmaceutical Industries Ltd. TARO 2.0%
14.6% Mylan N.V. MYL 35.6%
10.2% Impax Laboratories Inc. IPXL 36.2%
8.1% Sagent Pharmaceuticals Inc. SGNT 37.5%
7.7% Akorn Inc. AKRX 34.7%
5.2% Abbott Laboratories ABT 20.9%
3.6% Mallinckrodt plc MNK 51.6%
3.0% Lannett Co Inc LCI 58.1%
2.5% Sanofi American Depositary Shares (Each repstg one-half of one) SNY 19.5%
1.7% Teva Pharmaceutical Industries Limited American Depositary Share TEVA 13.8%
1.3% Cambrex Corporation CBM 13.6%
1.0% The Medicines Company MDCO 16.3%
0.4% Endo International PLC ENDP 81.1%

Quotes delayed 15 mins. Currently Jun 28, 2016 5:30:18 AM. Fields are marked with -- when data is unavailable.